Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04831567 | Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors(MIBNET) | Phase 2 | withdrawn | Apr 5, 2021 | AC Camargo Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced… | Phase 1 | terminated | Feb 23, 2017 | SignalRX Pharmaceuticals, Inc. | Lack of recruitment and sponsor's priority changes | Enrollment / accrual |
| NCT04150562 | Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma | Phase 2 | terminated | Nov 4, 2019 | National Cancer Institute (NCI) | This study was terminated early due to manufacturer withdrawal of support (study medication) due to… | Drug supply |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and…(RENACOL) | Phase 1 / Phase 2 | withdrawn | Nov 3, 2021 | Faron Pharmaceuticals Ltd | Since no patients have been enrolled in RENACOL, and safety and tolerability data is rapidly… | Safety / toxicity |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Apollomics (Australia) Pty. Ltd. | Study terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04… | Phase 3 | withdrawn | Jul 10, 2020 | Shanghai Henlius Biotech | The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been… | Other (stated, no rule matched) |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed…(0927GCC) | Phase 2 | terminated | Nov 4, 2010 | University of Maryland, Baltimore | low accrual | Enrollment / accrual |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Oct 20, 2017 | Genoscience Pharma | only phase 1b was completed and the phase 2 will be an another study, finally | Other (stated, no rule matched) |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | Phase 2 | withdrawn | Apr 2, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | accrual on hold | Enrollment / accrual |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant… | Phase 1 / Phase 2 | withdrawn | Apr 12, 2021 | Elpiscience Biopharma, Ltd. | Sponsor's clinical development strategy adjustment | Sponsor / business decision |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | Phase 2 | withdrawn | Aug 1, 2016 | Wake Forest University Health Sciences | no accrual rate | Enrollment / accrual |
| NCT04625543 | Neoadjuvant Immunotherapy to ESCC | Phase 2 | withdrawn | Nov 12, 2020 | Qilu Hospital of Shandong University | insufficient money | Other (stated, no rule matched) |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on… | Phase 1 / Phase 2 | terminated | Apr 2, 2014 | Polaris Group | not stated | Not stated |
| NCT03630809 | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | Phase 2 | terminated | Aug 15, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Quality of the data originating from prior versions of the protocol has been affected by protocol… | COVID-19 / pandemic |
| NCT02704130 | TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | N/A | terminated | Mar 9, 2016 | Wake Forest University Health Sciences | Lack of funding | Funding |
| NCT04003025 | Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)(HNCAX01) | — | withdrawn | Jul 1, 2019 | Instituto do Cancer do Estado de São Paulo | The proposed analysis was not feasible. | Other (stated, no rule matched) |
| NCT03000179 | Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma | Phase 2 | terminated | Dec 21, 2016 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT04272333 | Intratumoral Microdosing of Motolimod in HNSCC | Early Phase 1 | terminated | Feb 17, 2020 | Presage Biosciences | Partner Termination | Other (stated, no rule matched) |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer… | Phase 3 | terminated | Feb 3, 2006 | Sumitomo Pharma Co., Ltd. | not stated | Not stated |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With… | Phase 1 / Phase 2 | terminated | Oct 16, 2018 | Elevar Therapeutics | Terminated after completion of Part 1 due to a change in research plan. | Other (stated, no rule matched) |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | N/A | terminated | Feb 25, 2019 | IHU Strasbourg | COVID Pandemy - recruitment issue | COVID-19 / pandemic |
| NCT04428047 | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell…(ICING) | Phase 2 | terminated | Jun 11, 2020 | UNICANCER | Sponsor decision following information on cases of hyperprogression and early toxicities with… | Safety / toxicity |
| NCT02824575 | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast… | Phase 1 | terminated | Jul 6, 2016 | Montefiore Medical Center | Unfortunately, Deciphera management decided to not move forward with the rebastinib program and are… | Other (stated, no rule matched) |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT03334409 | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney… | Phase 2 | terminated | Nov 7, 2017 | Academic and Community Cancer Research United | Due to loss of funding from the private foundation source | Funding |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | Phase 2 | terminated | Jan 9, 2020 | NanOlogy, LLC | Lack of enrollment | Enrollment / accrual |
| NCT04266470 | Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region | N/A | withdrawn | Feb 12, 2020 | Wake Forest University Health Sciences | Study is no longer feasible at our site. | Other (stated, no rule matched) |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Sep 11, 2017 | NYU Langone Health | The study was stopped earlier than anticipated due to slow accrual | Enrollment / accrual |
| NCT04231929 | BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre…(BIOPEARL-FIRST) | N/A | withdrawn | Jan 18, 2020 | Terumo Europe N.V. | Study cancelled by Sponsor decision | Sponsor / business decision |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin… | Phase 2 | terminated | Dec 1, 2016 | G1 Therapeutics, Inc. | Primary Analysis and survival follow up completed per protocol. Not stopped due to safety concerns | Safety / toxicity |
| NCT02584829 | Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without… | Phase 1 / Phase 2 | terminated | Oct 23, 2015 | Fred Hutchinson Cancer Center | Terminated due to loss in funding | Funding |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors…(ILIAD) | Phase 1 | terminated | Nov 8, 2018 | Mendus | Decision made not to move to Phase 2 | Other (stated, no rule matched) |
| NCT03138538 | M8891 First in Human in Solid Tumors(M8891) | Phase 1 | terminated | May 3, 2017 | EMD Serono Research & Development Institute, Inc. | As part of a portfolio-level management of the company's oncology pipeline, it was decided to stop… | Sponsor / business decision |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine… | Phase 1 | withdrawn | Apr 28, 2015 | Washington University School of Medicine | Drugs not available | Other (stated, no rule matched) |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | Phase 2 | terminated | Jun 1, 2015 | TC Biopharm | not stated | Not stated |
| NCT03733119 | ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative… | Phase 2 | terminated | Nov 7, 2018 | University of Wisconsin, Madison | Slow accrual | Enrollment / accrual |
| NCT03979547 | EXALT: EXercise Attenuates Liver Tumors Trial(EXALT) | N/A | terminated | Jun 7, 2019 | Milton S. Hershey Medical Center | Recruitment challenges | Enrollment / accrual |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III… | Phase 2 | withdrawn | Jul 19, 2018 | City of Hope Medical Center | Safety concerns | Safety / toxicity |
| NCT01954173 | Adjuvant Radiation for High Risk Bladder Cancer | N/A | terminated | Oct 1, 2013 | Emory University | Slow accrual | Enrollment / accrual |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Phase 1 | withdrawn | Nov 2, 2020 | HonorHealth Research Institute | Salarius discontinued support | Other (stated, no rule matched) |
| NCT03784417 | EUS-guided Laser Ablation in Pancreatic Adenocarcinoma | N/A | terminated | Dec 21, 2018 | Catholic University of the Sacred Heart | device unavalaible | Other (stated, no rule matched) |
| NCT04525391 | AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer(SUKSES-N5) | Phase 2 | terminated | Aug 25, 2020 | Se-Hoon Lee | Recommended completion of the study due to SUSAR occurring in other clinical trials conducted with… | Other (stated, no rule matched) |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Calithera Biosciences, Inc | Slow Enrollment | Enrollment / accrual |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | Phase 2 | withdrawn | Jan 30, 2017 | Guru Sonpavde | Principal investigator left lead institution and efforts to open the protocol at another… | Investigator |
| NCT04506983 | GPC3-CAR-T Cells for the Hepatocellular Carcinoma | Phase 1 | suspended | Aug 10, 2020 | Beijing Tsinghua Chang Gung Hospital | Adjust the plan | Other (stated, no rule matched) |
| NCT03619044 | The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor…(REVER) | N/A | terminated | Aug 7, 2018 | Institut Claudius Regaud | Slow recruitment rate | Enrollment / accrual |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable… | Phase 2 | withdrawn | Oct 8, 2019 | Roswell Park Cancer Institute | implementation issues | Other (stated, no rule matched) |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | Phase 2 / Phase 3 | withdrawn | Oct 16, 2019 | MacroGenics | Change in study design | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated May 19, 2022source: clinicaltrials